The $1.8 billion all-stock merger between Supernus and Indivior brings two CNS portfolios together across neurological and addiction indications, with a stated plan to deliver cost synergies and broaden pipeline execution. Indivior shareholders will receive 0.2683 shares of Supernus per Indivior share, and the combined entity is expected to close in the second half of 2026 subject to regulatory approvals. Supernus brings an FDA-approved apomorphine infusion device program for Parkinson’s motor fluctuations, while Indivior contributes buprenorphine-based extended-release injection programs and other addiction therapies. The deal is positioned to create operational efficiencies and concentrate resources into R&D. For the CNS market, the transaction signals consolidation as companies seek scale in commercial operations while managing patent cliffs and pipeline attrition risk.